The current contribution of molecular factors to risk estimation in neuroblastoma patients
- 1 October 1997
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 33 (12), 2092-2097
- https://doi.org/10.1016/s0959-8049(97)00237-2
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Expression of the Gene for Multidrug-Resistance–Associated Protein and Outcome in Patients with NeuroblastomaNew England Journal of Medicine, 1996
- Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas.Journal of Clinical Oncology, 1996
- trk A Gene expression in neuroblastoma. The clinical significance of an immunohistochemical studyCancer, 1995
- Unfavorable DNA ploidy and Ha-ras P21 findings in neuroblastomas detected through mass screeningCancer, 1995
- Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastomaMedical and Pediatric Oncology, 1995
- Prognostic Factors in Metastatic NeuroblastomaJournal of Pediatric Hematology/Oncology, 1992
- Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study.Journal of Clinical Oncology, 1991
- Tumour karyotype discriminates between good and bad prognostic outcome in neuroblastomaBritish Journal of Cancer, 1988
- Association of Multiple Copies of the N-mycOncogene with Rapid Progression of NeuroblastomasNew England Journal of Medicine, 1985
- Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma.Proceedings of the National Academy of Sciences, 1984